Abstract
Background: Composite responder endpoints feature frequently in rheumatology due to the multifaceted nature of many of these conditions. Current analysis methods used to analyse these endpoints discard much of the data used to classify patients as responders; they are therefore highly inefficient and result in low power. Methods: We highlight a novel augmented methodology that uses more of the information available to improve the precision of reported treatment effects. Since these methods are more challenging to implement, we have developed free, user friendly software available in a web-based interface. The software consists of two programs: one that supports the analysis of responder endpoints; the second is used for sample size estimation. We demonstrate the augmented analysis method and its software using the MUSE study, a phase IIb trial in patients with systemic lupus erythematosus. Results: We show the software can be used to analyse the trial with efficiency gains translating to a reduction in required sample size of 63%. Furthermore, we illustrate how the software can be used to choose the sample size needed in a future trial that will use the novel approach as the primary analysis method. Conclusion: We encourage trialists to utilise the software we have developed to implement augmented methodology in future studies to improve efficiency.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was funded by NIHR Cambridge Biomedical Research Centre (BRC). The funding body did not have a role in the design of the study, analysis, interpretation of data or writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors do not own the trial data used in the manuscript to illustrate the software, so we are unable to make it available.
